Literature DB >> 9705428

Modification of results of drug susceptibility tests by coexistence of Mycobacterium avium complex with Mycobacterium tuberculosis in a sputum sample: case report and experimental considerations.

K Suzuki1, T Kimoto, K Tsuyuguchi, H Matsumoto, A Niimi, E Tanaka, T Murayama, R Amitani.   

Abstract

We report on a patient whose sputum contained both Mycobacterium tuberculosis and Mycobacterium avium complex (MAC). The MAC failed to be detected by the PCR-based AMPLICOR test. The unrecognized coexistence of MAC in the sample modified the results of drug susceptibility tests. Experiments revealed that the presence of both M. tuberculosis and MAC was not detected by the AMPLICOR test under certain conditions.

Entities:  

Mesh:

Year:  1998        PMID: 9705428      PMCID: PMC105198     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Is PCR a useful tool for the diagnosis of tuberculosis in 1995?

Authors:  J Grosset; Y Mouton
Journal:  Tuber Lung Dis       Date:  1995-06

2.  Resistance to antituberculosis drugs in Japan.

Authors:  K Hirano; Y Kazumi; C Abe; T Mori; M Aoki; T Aoyagi
Journal:  Tuber Lung Dis       Date:  1996-04

3.  Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche PCR-microwell plate hybridization method (AMPLICOR MYCOBACTERIUM) for direct detection of mycobacteria.

Authors:  S Ichiyama; Y Iinuma; Y Tawada; S Yamori; Y Hasegawa; K Shimokata; N Nakashima
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

4.  Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens.

Authors:  F Z Badak; D L Kiska; S Setterquist; C Hartley; M A O'Connell; R L Hopfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

5.  Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.

Authors:  K Suzuki; K Tsuyuguchi; H Matsumoto; T Yamamoto; T Hashimoto; E Tanaka; R Amitani; F Kuze
Journal:  Int J Tuberc Lung Dis       Date:  1997-10       Impact factor: 2.373

6.  Selective inhibition of the Mycobacterium tuberculosis complex by p-nitro-alpha-acetylamino-beta-hydroxypropio phenone (NAP) and p-nitrobenzoic acid (PNB) used in 7H11 agar medium.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Res Microbiol       Date:  1989 Jul-Aug       Impact factor: 3.992

7.  Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test.

Authors:  C Abe; K Hirano; M Wada; Y Kazumi; M Takahashi; Y Fukasawa; T Yoshimura; C Miyagi; S Goto
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

8.  In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.

Authors:  F Kuze; T Kurasawa; K Bando; Y Lee; N Maekawa
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

9.  Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method.

Authors:  S B Walters; B A Hanna
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

10.  [Reproducibility of MTD system for detection of Mycobacterium tuberculosis: a cooperative study among six laboratories].

Authors:  C Abe; T Mori; E Fujii; M Asaba; H Utagawa; K Okazawa; S Hiyoshi; K Hoshino; Y Ashihara; Y Sakai
Journal:  Kekkaku       Date:  1995-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.